J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Shots: J&J has entered into a definitive agreement to acquire Halda Therapeutics, strengthening its oncology pipeline As per the deal, J&J will acquire Halda for $3.05B in cash, with the deal treated as a business combination & expected to close in the coming months Acquisition will add Halda’s Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform…

ByRidhi RastogiNovember 18, 2025

NEWS

Day One Biopharmaceuticals to Acquire Mersana Therapeutics for ~$285M

Shots: Day One has entered into a definitive merger agreement to acquire Mersana, delisting Mersana from the public market & making it a wholly owned subsidiary upon deal completion As per the deal, Day One will acquire Mersana for $25/share plus a CVR of ~$30.25/share tied to certain clinical development, regulatory, & commercial milestones for…

ByRidhi RastogiNovember 13, 2025

NEWS

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Shots: Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decade Sandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform…

ByDipanshu DixitNovember 5, 2025

NEWS

Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement

Shots: Metsera has declared Novo Nordisk’s unsolicited ~$9B acquisition proposal, valuing shares up to $77.75, as a “Superior Company Proposal” than its existing Pfizer Merger Agreement The 2-step proposal incl. an initial $56.5/share cash payment & issuance of non-voting preferred stock for 50% of Metsera’s share capital, followed by a CVR of ~$21.25/share in cash…

ByRidhi RastogiOctober 31, 2025

NEWS

Thermo Fisher Scientific to Acquire Clario for ~$9.4B

Shots: Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after…

ByRidhi RastogiOctober 29, 2025

NEWS

Eli Lilly Strengthens its Gene Therapy Capabilities with Adverum Acquisition

Shots: Eli Lilly has entered into a definitive agreement to acquire Adverum Biotechnologies, incl. its asset Ixo-vec As per the deal, Lilly will acquire Adverum for $3.56/share plus a CVR of ~$8.91 per share, tied to milestones: for ~$1.78 per CVR on Ixo-vec’s FDA approval within 7yrs. of closing & ~$7.13 per CVR upon achieving $1B…

ByRidhi RastogiOctober 27, 2025

NEWS

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Shots: Novartis has agreed to acquire Avidity Biosciences, strengthening its neuroscience pipeline with Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform & 3 late-stage programs As per the deal, Novartis will acquire Avidity for $72/share, valuing the company at ~$12B with an enterprise value of ~$11B; closing expected in H1’26 Before the merger, Avidity will transfer its early-stage precision…

ByRidhi RastogiOctober 27, 2025

NEWS

Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Shots: Alkermes has entered into a definitive agreement to acquire Avadel, incl. its asset Lumryz, accelerating its entry into the sleep medicine market As per the deal, Alkermes will acquire Avadel for $18.5/share, along with one non-tradeable CVR of $1.5/share tied to Lumryz’s US FDA approval for idiopathic hypersomnia in adults by 2028 end, representing…

ByRidhi RastogiOctober 24, 2025

NEWS

Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline

Shots: Ipsen enters into a definitive share purchase agreement with ImCheck Therapeutics to acquire later's all issued and outstanding shares, including lead candidate ICT01, a P-I/II therapy for 1L AML pts ineligible for intensive CT As per the deal, shareholders of ImCheck Therapeutics will receive €350M ($406.62M) in closing purchase price, with additional deferred payments…

ByDipanshu DixitOctober 23, 2025

NEWS

Boston Scientific to Acquire Nalu Medical for ~$533M

Shots: Boston Scientific has entered into a definitive agreement to acquire Nalu Medical, expanding its neuromodulation portfolio for chronic pain with the Nalu Neurostimulation System As per the deal, Boston Scientific will acquire the remaining equity of Nalu Medical for ~$533M in cash, in which it has been a strategic investor since 2017; closing expected…

ByRidhi RastogiOctober 21, 2025

J&J Accelerates Cancer Innovation with $3.05B Halda Therapeutics Acquisition

Day One Biopharmaceuticals to Acquire Mersana Therapeutics for ~$285M

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement

Thermo Fisher Scientific to Acquire Clario for ~$9.4B

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Alkermes to Acquire Avadel Pharmaceuticals for ~$2.1B, Marking its Entry in Sleep Medicine Market

Ipsen Acquires ImCheck Therapeutics, Enhancing its Oncology Leadership and Strengthening its Pipeline

Boston Scientific to Acquire Nalu Medical for ~$533M

Contact US

FOLLOW US